Lates News

Recently, the National Medical Products Administration approved the conditional marketing authorization of the innovative drug, Atezolizumab (trade name: Atesinuo), submitted by Bayer HealthCare Pharmaceuticals Inc. through the priority review process. The drug is indicated as a monotherapy for the treatment of unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with HER2 (ERBB2) mutations who have received at least one prior systemic therapy. The marketing of this drug provides patients with a new treatment option. (National Medical Products Administration)